Lilly drug slows Alzheimer's progression by 35% in trial

Canada News News

Lilly drug slows Alzheimer's progression by 35% in trial
Canada Latest News,Canada Headlines
  • 📰 Reuters
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 97%

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease.

In the donanemab treatment group, Lilly said brain swelling, a known side effect of drugs of this type, occurred in 24% of the participants, with 6.1% experiencing symptoms. Brain bleeding occurred in 31.4% of the donanemab group and 13.6% of the placebo group.

Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute, which is running an Alzheimer's prevention study of donanemab in presymptomatic patients, said he was "very excited" about the findings. "Clearly, one saw benefits here, but there is some risk that needs to be considered." Study participants received a monthly intravenous infusion of donanemab. When follow-up brain scans showed that amyloid had been removed, the treatment was stopped and volunteers were moved to the placebo-arm of the study. Half of the trial participants had no evidence of amyloid plaques at 12 months, the company said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Reuters /  🏆 2. in US

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Read more »

Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysExperimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Read more »

Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialEli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Read more »

Eli Lilly's diabetes drug could revolutionize the US weight loss marketEli Lilly's diabetes drug could revolutionize the US weight loss marketEli Lilly’s diabetes drug delivers promising results in a recent clinical trial. The company hopes it will be added to the U.S. weight loss market soon.
Read more »

Travere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drugTravere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drugTravere Therapeutics Inc.’s stock tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statistically...
Read more »

Eli Lilly stock jumps 4% premarket on news of positive results in late-stage trial of Alzheimer’s disease treatmentEli Lilly stock jumps 4% premarket on news of positive results in late-stage trial of Alzheimer’s disease treatmentEli Lilly & Co.’s stock jumped 4% premarket Wednesday, after the company announced positive data from a late-stage trial of its Alzheimer’s disease treatment...
Read more »



Render Time: 2025-03-01 01:54:06